{
    "Trade/Device Name(s)": [
        "Rapid Fentanyl (FYL) Test Strip",
        "Rapid Fentanyl (FYL) Test Dipcard"
    ],
    "Submitter Information": "Co-Innovation Biotech Co., Ltd.",
    "510(k) Number": "K231904",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220046"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "February 2, 2024",
    "Summary Letter Received Date": "February 2, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay",
        "Antigen-antibody immunochemistry"
    ],
    "Methodologies": [
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Strip",
        "Dipcard"
    ],
    "Document Summary": "FDA 510(k) summary for Co-Innovation Rapid Fentanyl (FYL) Test Strip and Dipcard for qualitative detection of fentanyl in human urine via lateral flow immunochromatographic assay.",
    "Indications for Use Summary": "Rapid screening test for the qualitative detection of fentanyl in human urine at 1 ng/mL cutoff, intended for prescription and point-of-care use; preliminary results require confirmatory testing by GC/MS or LC/MS.",
    "fda_folder": "Toxicology"
}